KDNY
Closed
Chinook Therapeutics Inc
40.39
0.00 (0.00%)
Last Update: 18 Aug 2023 16:30:00
Yesterday: 40.39
Day's Range: 40.39 - 40.39
Send
sign up or login to leave a comment!
When Written:
23.15
Chinook Therapeutics Inc is a clinical-stage biotechnology company that is focused on developing precision medicines for kidney diseases. The company was founded in 2019 and is headquartered in Vancouver, Canada, with additional offices in Seattle, US. Chinook Therapeutics is led by a team of experienced industry professionals and has partnerships with leading academic institutions and pharmaceutical companies.
The company's pipeline includes several drug candidates that target different aspects of kidney diseases, including IgA nephropathy, focal segmental glomerulosclerosis (FSGS), and lupus nephritis. Chinook Therapeutics is also developing novel therapies for rare kidney diseases, such as primary hyperoxaluria and C3 glomerulopathy.
Chinook Therapeutics has raised significant funding from investors, including Versant Ventures, Apple Tree Partners, and Samsara BioCapital. The company went public in 2020 and is listed on the Nasdaq Global Market under the ticker symbol "KDNY".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's pipeline includes several drug candidates that target different aspects of kidney diseases, including IgA nephropathy, focal segmental glomerulosclerosis (FSGS), and lupus nephritis. Chinook Therapeutics is also developing novel therapies for rare kidney diseases, such as primary hyperoxaluria and C3 glomerulopathy.
Chinook Therapeutics has raised significant funding from investors, including Versant Ventures, Apple Tree Partners, and Samsara BioCapital. The company went public in 2020 and is listed on the Nasdaq Global Market under the ticker symbol "KDNY".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








